Text Size: a  |   a 

FDA Approves Zinbryta

June 7, 2016

Our last update on Zinbryta stated that it was still being evaluated for MS treatment in America and that The European Medicines Agency had also endorsed the injection. The FDA has now approved of Zinbryta and it is available as treatment for adults who suffer from forms of relapsing multiple sclerosis.

Since it is a self-injected form of treatment, it “provides an additional choice to patients who may require a new option for treatment,” said the director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research, Billy Dunn, MD.

It was noted by the FDA that Zinbryta should be used by patients who do not respond well to 2 or more types of multiple sclerosis drug treatments. This is because the drug has a possibility to lead to liver injury as well as other serious immune conditions. These include conditions like noninfectious colitis, skin reactions and lymph node enlargement.

Other common symptoms of the drug include upper respiratory tract infection, influenza, cold symptoms, rash, dermatitis, depression and increased alanine aminotransferase.

While Zinbryta is currently only available under the Risk Evaluation and Mitigation Strategy program, blood tests should also be conducted by health care professionals before taking the medication, monthly and up to 6 months after the last dose.